Study S001441

A Multicenter, Randomized, Double-blind, Placebo- Parallel Controlled, Phase II Study to Evaluate the Efficacy and Safety of HRS9531 Tablet in Obese Subjects

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT06841445
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: TRIPLE
Status: COMPLETED
Enrollment: 166
Start: 2025-04-07
Primary completion: 2026-01-08
Lead sponsor: Fujian Shengdi Pharmaceutical Co., Ltd.
Conditions: Chronic Management of Body Weight
Interventions: DRUG:HRS9531 Tablet; DRUG:HRS9531 Tablet placebo
Results posted: FALSE
Individual participant data sharing: UNDECIDED

Registered primary outcomes

Percentage Change from baseline in body weight after 26 weeks of treatment [after 26 weeks of treatment]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.